Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02798289 · ClinicalTrials.gov registry record · NA

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

A NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca, sponsored by Oculeve.

Completed
Registry status
NA
Development phase
55
Enrollment target
2
Study locations

NCT02798289 is a NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca that has completed, run by Oculeve. The registered enrollment target is 55 participants, below the 159-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02798289, a NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca, has completed, sponsored by Oculeve.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.

Interventions

  • DEVICE Oculeve Intranasal Neurostimulator

Study Locations (2)

California

  • Sall Research Medical Center - Artesia
  • Aesthetic Eyecare Institute - Newport Beach

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2016-06
Est. Completion 2016-08
Phase NA

Sponsor

Oculeve

5 total trials

What the Registry Record Tells You About NCT02798289

The ClinicalTrials.gov registry entry for NCT02798289 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 159-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (65% lower). The listed sponsor is Oculeve, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Dry Eye Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Oculeve Intranasal Neurostimulator is the first listed.

NCT02798289 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02798289 about?

NCT02798289 is a clinical study titled "Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator". The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.

What is the current status of trial NCT02798289?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2016-06. Estimated completion is 2016-08.

What conditions does trial NCT02798289 study?

This clinical trial studies the following conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca.

What interventions are being tested in trial NCT02798289?

The interventions under investigation include: Oculeve Intranasal Neurostimulator (DEVICE).

Who is sponsoring clinical trial NCT02798289?

This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02798289 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.